Filing Analysis
Fractyl Health announced its Q4 and full-year 2025 financial results and provided a corporate update. The company also updated its corporate presentation to include new post hoc analyses from its REMAIN-1 clinical study.
Key Facts
- Financial results for the quarter and full year ended December 31, 2025, were announced on March 24, 2026.
- Updated corporate presentation for use in meetings with investors and analysts.
- Provided new post hoc analyses for the REMAIN-1 Midpoint Cohort 6-month results.
- Analyses evaluated the relationship between treatment effect, procedural dose (length of duodenal ablation), and prior GLP-1-induced weight loss.
Fractyl Health, Inc. received a deficiency notice from Nasdaq on March 13, 2026, because its common stock failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. The company has 180 days, until September 9, 2026, to regain compliance or face potential delisting.
Red Flags
- Minimum bid price deficiency (stock trading below $1.00).
- Explicit mention of a potential reverse stock split to cure the deficiency.
- Risk of delisting if compliance is not met within the 180-day grace period.
Key Facts
- Notice received from Nasdaq on March 13, 2026, regarding non-compliance with Rule 5450(a)(1).
- Common stock bid price was below $1.00 for 30 consecutive business days.
- The compliance deadline is September 9, 2026.
- To regain compliance, the stock must close at $1.00 or higher for at least 10 consecutive business days.
- The company may transfer to the Nasdaq Capital Market or effect a reverse stock split to resolve the deficiency.
Fractyl Health announced the completion of participant randomization for its REMAIN-1 Pivotal Cohort, a study evaluating the Revita procedure for weight maintenance after GLP-1 therapy discontinuation. The company also provided updated 2026 clinical and regulatory milestones and reiterated its current cash guidance.
Key Facts
- Completion of participant randomization in the REMAIN-1 Pivotal Cohort as of February 26, 2026.
- The REMAIN-1 study is a randomized, double-blind, sham-controlled trial.
- The study specifically targets weight maintenance in patients who have discontinued GLP-1 therapy.
- The company provided updated guidance on 2026 Revita clinical and regulatory milestones.
- Management reiterated previous cash guidance, suggesting no immediate change to their financial runway expectations.